These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20436290)

  • 21. Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation.
    Dastidar SG; Raghunathan D; Nicholson J; Hupp TR; Lane DP; Verma CS
    Cell Cycle; 2011 Jan; 10(1):82-9. PubMed ID: 21191186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.
    ElSawy KM; Lane DP; Verma CS; Caves LS
    J Phys Chem B; 2016 Jan; 120(2):320-8. PubMed ID: 26701330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Dynamic Features of Apo and Bound MDM2 Protein Reveal the Mechanism of Inhibitor Recognition for Anti-Cancer Activity.
    I El Habbash A; El Rashedy A; Soliman MES
    Curr Med Chem; 2023; 30(10):1193-1206. PubMed ID: 35702782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding Kinetics of the Intrinsically Disordered p53 Family Transactivation Domains and MDM2.
    Åberg E; Karlsson OA; Andersson E; Jemth P
    J Phys Chem B; 2018 Jul; 122(27):6899-6905. PubMed ID: 29878773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of a novel MDM2 binding peptide based on the p53 family.
    Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
    Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.
    Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR
    Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bridging Microscopic and Macroscopic Mechanisms of p53-MDM2 Binding with Kinetic Network Models.
    Zhou G; Pantelopulos GA; Mukherjee S; Voelz VA
    Biophys J; 2017 Aug; 113(4):785-793. PubMed ID: 28834715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Nonnative Interactions on the Binding Kinetics of Intrinsically Disordered p53 with MDM2: Insights from All-Atom Simulation and Markov State Model Analysis.
    Xu Q; Yang M; Ji J; Weng J; Wang W; Xu X
    J Chem Inf Model; 2024 Jul; 64(13):5219-5231. PubMed ID: 38916177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 mRNA and p53 Protein Structures Have Evolved Independently to Interact with MDM2.
    Karakostis K; Ponnuswamy A; Fusée LT; Bailly X; Laguerre L; Worall E; Vojtesek B; Nylander K; Fåhraeus R
    Mol Biol Evol; 2016 May; 33(5):1280-92. PubMed ID: 26823446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.
    Dowarha D; Chou RH; Yu C
    PLoS One; 2020; 15(6):e0234152. PubMed ID: 32497081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 mRNA controls p53 activity by managing Mdm2 functions.
    Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
    Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding.
    Dastidar SG; Lane DP; Verma CS
    Cell Cycle; 2012 Jun; 11(12):2239-47. PubMed ID: 22617389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flexibility is important for inhibition of the MDM2/p53 protein-protein interaction by cyclic β-hairpins.
    Danelius E; Pettersson M; Bred M; Min J; Waddell MB; Guy RK; Grøtli M; Erdelyi M
    Org Biomol Chem; 2016 Nov; 14(44):10386-10393. PubMed ID: 27731454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation.
    Zheng J; Lang Y; Zhang Q; Cui D; Sun H; Jiang L; Chen Z; Zhang R; Gao Y; Tian W; Wu W; Tang J; Chen Z
    Genes Dev; 2015 Jul; 29(14):1524-34. PubMed ID: 26220995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The facile and visualizable identification of broad-spectrum inhibitors of MDM2/p53 using co-expressed protein complexes.
    Yang Y; Dong Z; Hu H; Peng J; Sheng Y; Tong Y; Yuan S; Li Z; Yang J; Wells T; Qu Y; Farrell NP; Liu Y
    Analyst; 2019 Jun; 144(12):3773-3781. PubMed ID: 31089613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.